Absence of mucosal inflammation in uncomplicated diverticular disease

Digestive Diseases and Sciences

Volumn 56, Issue 7, 2011, Pages 2098-2103

  Elli, Luca ^a   Roncoroni, Leda ^a,b   Bardella, Maria Teresa ^a,b   Terrani, Claudia ^a   Bonura, Antonella ^a   Ciulla, Michele ^b   Marconi, Stefano ^c   Piodi, Luca ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Medical Division   (Italy)

Author keywords

Cytokine; Diverticula; Diverticular disease; Inflammation; Transglutaminase type 2

Indexed keywords

CASPASE 9; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; DIVERTICULOSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOCHEMISTRY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; NICK END LABELING; PRIORITY JOURNAL;

ADULT; AGED; APOPTOSIS; BIOPSY; CASPASE 9; COLON; CYTOKINES; DIVERTICULOSIS, COLONIC; DIVERTICULUM, COLON; FEMALE; GTP-BINDING PROTEINS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; TRANSGLUTAMINASES;

EID: 79959756278     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-010-1547-0     Document Type: Article

References (30)

1. Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamagna G. Review article: Uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther. 2006;23:1379-1391.
2. Commane DM, Arasaradnam RP, Mills S, Mathers JC, Bradburn M. Diet, ageing and genetic factors in the pathogenesis of diverticular disease. World J Gastroenterol. 2009;15:2479-2488.
3. Bassotti G, Chistolini F, Morelli A. Pathophysiological aspects of diverticular disease of colon and role of large bowel motility. World J Gastroenterol. 2003;9:2140-2142. (Pubitemid 37321432)
4. Eggenberger JC. Diverticular disease. Curr Treat Options Gastroenterol. 1999;2:507-516.
5. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol. 2008;103:1550-1556. (Pubitemid 351813921)
6. Salem TA, Molloy RG, O'Dwyer PJ. Prospective, five-year follow- up study of patients with symptomatic uncomplicated diverticular disease. Dis Colon Rectum. 2007;50:1460-1464. (Pubitemid 47472385)
7. Spiller R. How inflammation changes neuromuscular function and its relevance to symptoms in diverticular disease. J Clin Gastroenterol. 2006;40:S117-S120. (Pubitemid 44174904)
8. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913-920. (Pubitemid 46440872)
9. Di Mario F, Comparato G, Fanigliulo L, et al. Use of mesalazine in diverticular disease. J Clin Gastroenterol. 2006;40:S155-S159. (Pubitemid 44174911)
10. Kohler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: results of a consensus development conference. The scientific committee of the European Association for Endoscopic Surgery. Surg Endosc. 1999;13:430-436.
11. Ierardi E, Hassan C, Zullo A, et al. Segmental colitis associated with diverticula: a rare clinical entity and a new challenge for the gastroenterologist. Dig Liver Dis. 2009;41:794-797.
12. Ciulla MM, Montelatici E, Ferrero S, et al. Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction. J Transl Med. 2008;6:30.
13. Roncoroni L, Elli L, Dolfini E, et al. Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line. Liver Int. 2008;28:1426-1436.
14. Floch MH, White JA. Management of diverticular disease is changing. World J Gastroenterol. 2006;12:3225-3228. (Pubitemid 43881347)
15. Makapugay LM, Dean PJ. Diverticular disease-associated chronic colitis. Am J Surg Pathol. 1996;20:94-102. (Pubitemid 26007715)
16. Kealy WF. Lymphoid tissue and lymphoid-glandular complexes of the colon: relation to diverticulosis. J Clin Pathol. 1976;29:245-249.
17. Cianci R, Iacopini F, Petruzziello L, Cammarota G, Pandolfi F, Costamagna G. Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol. 2009;44:108-115.
18. Pezzilli R, Barassi A, Morselli Labate AM, et al. Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci. 2008;53:47-51. (Pubitemid 350265648)
19. Lahat A, Avidan B, Bar-Meir S, Chowers Y. Long-standing colonic inflammation is associated with a low prevalence of diverticuli in inflammatory bowel disease patients. Inflamm Bowel Dis. 2007;13:733-736. (Pubitemid 46909988)
20. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40:312-316. (Pubitemid 44309523)
21. Comparato G, Fanigliulo L, Cavallaro LG, et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci. 2007;52:2934-2941. (Pubitemid 47512549)
22. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci. 2007;52:671-674.
23. Bradesi S, Mayer EA. Novel therapeutic approaches in IBS. Curr Opin Pharmacol. 2007;7:598-604. (Pubitemid 350185855)
24. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920-1925. (Pubitemid 40404695)
25. Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin Immunol. 2009;132:1-9.
26. Yan BM, Shaffer EA. Primary eosinophilic disorders of the gastrointestinal tract. Gut. 2009;58:721-732.
27. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther. 2008;7:2649-2661.
28. Goriely S, Cavoy R, Goldman M. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders. Allergy. 2009;64:702-709.
29. Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci. 2009;14:2923-2934.
30. Elli L, Bergamini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis. 2009;41:541-550.